Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

Cancer, a rare occurrence? Unfortunately, not anymore. According to recent findings from an analysis published in The Lancet, cancer is one of the top 10 causes of death among Indian children. This is an alarming statistic, signalling an under-recognised public health problem. Data in the Global Burden of Disease Study 2023 noted that even as infectious diseases decline, noncommunicable diseases like cancer are emerging as a serious threat to child survival and well-being. In India, this epidemiological shift is particularly concerning in the context of childhood cancers. Despite being rare, they are highly treatable when detected in the early stages—yet most cases are diagnosed late.

As per the Indian Council of Medical Research’s National Centre for Disease Informatics and Research (ICMR-NCDIR), childhood cancers accounted for 3–5 per cent of cancer cases reported in India in 2022. The country sees an estimated 50,000 to 60,000 cases every year among children aged 0–14 years. This makes it one of the highest burdens globally. In 2023, 377,000 cases of childhood cancer were reported globally, along with 144,000 deaths, according to The Lancet research paper.

Read more: 3 Children In Every 4 Minutes Are Diagnosed With Cancer, That's What Makes Awareness Important Says Doctor

Hidden cancer burden in India

When it comes to childhood cancers in India, leukaemia, or blood cancers, are the most common, followed by lymphomas and tumours of the central nervous system. Collectively, these categories comprise most cases of childhood cancers in the country. The statistics vary across regions, with Delhi reporting the highest number of cases due to better diagnostic facilities. However, experts believe that the actual burden is likely to be much higher. Incomplete cancer registration and limited access to proper diagnostic facilities in underserved and rural areas are to blame for delayed diagnosis.

Why is childhood cancer detected late in India?

Experts say that cancer deaths in India can largely be attributed to delayed diagnosis. Early symptoms of cancer in children include fatigue, fever, unexplained weight loss, and swelling in certain body parts. These symptoms are often overlooked, leading to delays at multiple levels. According to the ICMR 2022 factsheet, a significant proportion of children reach hospitals only at advanced stages of the disease. By then, treatment becomes more complex, more expensive, and less likely to succeed.

Access to cancer care for children

Access to cancer care for children is uneven in India. Paediatric oncology services are largely limited to hospitals in tier-one cities, forcing families from rural areas and smaller towns to travel in order to access proper treatment. This imbalance results in delayed care, especially for economically vulnerable families. Financial limitations are another barrier in the process—even if treatment costs are subsidised, expenses such as travel, accommodation, and loss of income can be overwhelming.

Read more: 41 million children aged 5-19 living with high BMI in India: Study

Irregular survival patterns

Globally, survival rates for childhood cancers exceed 80 per cent in high-income countries. In India, outcomes are uneven. The ICMR 2022 factsheet noted that survival depends on the stage of diagnosis, type of cancer, and where the child is treated. Hospitals in India are reporting improving survival rates for certain forms of cancer, such as acute lymphoblastic leukaemia. The ICMR factsheet also highlights the need for a dedicated approach to paediatric cancer care, including better infrastructure, trained doctors, and stronger referral systems.

Indian weddings are a global sensation for all the taam-jhaam—the outfits, the music, the madness, and the unmatched vibe. In an ever-evolving culture, several new trends become a part of the wedding buzz in India. At a time when weight-loss drugs are the talk of the town, it is no surprise that they, too, have joined the list of new must-haves for Indian brides. For many soon-to-be brides and grooms, the pressure to look a class apart is always high. Amid the madness of wedding preparations, brides and grooms often miss the gym—weight-loss drugs come to their rescue.

India's Mounjaro brides

Clinics in metropolitan cities like Delhi and Mumbai are introducing weight-loss treatments into their traditional pre-bridal and bridal packages. Bridal packages initially focused on hair care, skincare, hair styling, and grooming—but they have now expanded to include shots of Mounjaro, a popular weight-loss drug. Some wellness centres in the city have advertised that they offer customised programmes combining workout routines, nutrition, and medication to help clients achieve desired results.

Doctors have noticed a clear rise in such inquiries. Several specialists report that a significant portion of their patients seeking obesity treatments are engaged couples working within a fixed timeline. While medical professionals acknowledge this demand, many emphasise that such treatments should only be prescribed when medically appropriate, rather than purely for cosmetic reasons.

Read more: India To Strictly Inspect GLP-1 Drugs To Curb Misuse: Govt Flags Risks Amid Weight-loss Hype

The pressures of looking good at a wedding

Weddings in India are deeply rooted in tradition, elaborate, and often burdened by societal expectations around appearance. As a result, many resort to glycolic treatments, injections of Mounjaro, and sometimes even facial procedures for a bridal glow. However, weight-loss drugs serve a different purpose—they can boost a bride's confidence by helping her feel more comfortable in her own skin.

Others share similar experiences. Some individuals admitted that concerns about body image, often influenced by family expectations or societal standards, played a major role in their decision. In certain cases, weight became a factor in arranged marriage discussions, pushing individuals to seek faster solutions. However, most discontinued the injections shortly after their weddings.

Why are weight-loss drugs becoming so popular?

According to experts, the growing popularity of weight-loss drugs is linked to their increased availability. Globally, pharmaceutical companies have introduced their own versions of obesity treatments in India, and demand has risen drastically. At the same time, more affordable alternatives are being introduced by manufacturers to make these drugs accessible to a wider audience.

A word of caution

Despite the surge, experts warrant caution. Weight-loss drugs are intended to help clinically obese or significantly overweight individuals, as well as patients with type 2 diabetes and hypertension. These drugs are not meant to act as quick fixes for short-term aesthetic goals. Experts, therefore, stress the importance of using these drugs under expert guidance and supervision.

Misuse of weight-loss drugs

Doctors are also concerned about the misuse of weight-loss drugs—health authorities have started monitoring the sale and promotion of such medication, especially the cheaper versions on the market. Experts say that relying solely on these drugs instead of making essential lifestyle changes may not lead to sustainable results. For many, the appeal lies in convenience—maximum benefits with minimal effort. While these drugs may fit into a hectic routine, doctors continue to emphasise the need for a balanced approach to weight loss.

The UK National Health Service (NHS) is soon expected to roll out free weight-loss Wegovy jab to over a million people in England at risk of heart attacks and strokes.

The move is based on the recommendation of the National Institute for Health and Care Excellence (NICE), which said that overweight people with heart problems, or serious circulation problems in their legs, should have the weekly jab "as an extra layer of protection".

Developed by Danish drugmaker Novo Nordisk, Wegovy is primarily an antidiabetic medication used to treat Type 2 diabetes. People receiving the weight-loss drug Wegovy sustained weight loss for up to four years.

"We know that people who have already had a heart attack or stroke are living with real fear that it could happen again. The evidence from the clinical trial is compelling. It showed that people taking semaglutide alongside their existing heart medicines were significantly less likely to have another heart attack or stroke,” said Helen Knight, from NICE.

"Today's decision gives thousands of people in that situation an extra layer of protection, on top of the medicines they are already taking," she added.

Also read: Foundayo: US FDA Approves Eli Lilly’s GLP-1 Weight Loss Pill

Wegovy and Heart Risk

A November 2023 study, published in the New England Journal of Medicine, elicited a randomized clinical trial of tens of thousands of people, in which Wegovy - alongside existing heart medicines - was linked to a 20% reduced risk of heart attacks and strokes.

Importantly, benefits were seen early in the clinical trial, before significant weight loss occurred, suggesting the drug works directly on the heart and blood vessels, not just through weight loss, as per the NICE

The BBC reported that the UK faces a significant heart disease burden, and every year:

100,000 people get hospitalized due to heart attacks,

100,000 people experience a stroke

350,000 people live with peripheral arterial disease.

Sharon Hodgson, the health minister, said weight-loss drugs were a “gamechanger” and giving them to people at risk of heart attacks and strokes would be a “lifesaver”.

Also read: India To Strictly Inspect GLP-1 Drugs To Curb Misuse: Govt Flags Risks Amid Weight-loss Hype

Wegovy Is Top Weight-Loss Choice for US Teens

Only Wegovy has been approved by the US FDA for children aged 12 and older who are living with obesity. Since the approval in late 2022, the prescriptions have surged.

According to health data company Truveta, which reviewed medical records from 30 US health systems, prescriptions for Wegovy among teens jumped by 50 percent in 2024—rising from 9.9 per 100,000 adolescents in 2023 to 14.8 per 100,000 in 2024.

The first quarter of 2025 showed another increase, with the rate reaching 17.3 per 100,000.